---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-034316"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2023-10-13T23:59:59+00:00"
generated_at: "2026-06-09T23:49:20.497725+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma announces pediatric Vibativ safety study publication

## Summary
- First clinical study of Vibativ in children 2–17; single 10 mg/kg dose safe with no serious adverse events.
- Published in Antimicrobial Agents and Chemotherapy; 22 patients enrolled.
- Study found lower drug exposure in children vs adults, informing future dosing.
- Vibativ is FDA-approved for adult HABP/VABP and cSSSIs caused by gram-positive bacteria.

## SEC filing metadata
- accession: 0001628280-23-034316
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2023-10-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828023034316/0001628280-23-034316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828023034316/cpix-20231013.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-034316
- JSON: https://secwatch.observer/filing/0001628280-23-034316.json
- Plain text: https://secwatch.observer/filing/0001628280-23-034316.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.